ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements with these filters
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs has been assigned an ESG score of 63 out of 100 for FY 2026 by NSE Sustainability Ratings and Analytics Limited.
Laurus Labs has allotted 62,635 equity shares to employees upon the exercise of vested stock options under its ESOP schemes.
Laurus Labs announced the NCLT has issued an order regarding its Composite Scheme of Arrangement. The court directed notices be served for the upcoming September hearing.
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore and EBITDA of ₹644 Crore. The results show 29% year-on-year revenue growth.
Laurus Labs delivered a strong Q1 FY27 with ₹2,026 Cr revenue (up 29% YoY), driven by robust CDMO growth. EBITDA margins expanded to 31.8% due to favorable product mix and operational leverage.
Independent Director Dr. Rajesh Koshy Chandy retired from Laurus Labs on July 26, 2026. This follows the completion of his second term.
Laurus Labs Ltd reported revenue from operations of ₹2,026 Cr (+29.1% YoY) and net profit of ₹362.1 Cr (+123.9% YoY) for Q1 FY27.
Routine quarterly shareholding pattern filing by Laurus Labs Ltd for the quarter ending June 30, 2026. No significant corporate action or financial event occurred.
Laurus Labs scheduled a board meeting on July 24, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Laurus Labs' credit ratings for bank facilities were reaffirmed by CARE Ratings. The reaffirmation reflects improved FY26 performance and stronger debt coverage.
Laurus Labs appointed two new Independent Directors at its 21st AGM. The appointments, effective July 2, 2026, are for five-year terms.
Laurus Labs concluded its 21st AGM, approving financial statements and interim dividends. Voting results were scrutinized and all resolutions passed by requisite majority.
Laurus Labs submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details environmental, social, and governance performance in compliance with SEBI regulations.
Laurus Labs released its Integrated Annual Report for FY 2025-26. The report details strategic growth in CDMO and API segments alongside ESG milestones and operational highlights.
Laurus Labs Limited has scheduled its 21st Annual General Meeting for July 2, 2026. Key agenda items include adopting financial statements and approving director appointments.
Laurus Labs allotted 3,93,001 equity shares following the exercise of employee stock options. The company realized ₹12.40 Crore from the allotment across four ESOP grant schemes.
Laurus Labs debuted in the Dow Jones Best-in-Class (DJ BIC) World Index. This recognition highlights the company's strong ESG performance and ethical corporate governance commitment.
Laurus Labs delivered strong Q4 FY26 results with 23% annual revenue growth and significant EBITDA margin expansion to 26.8%, driven by a transforming CDMO business and generic portfolio ramp-up.
Laurus Labs Limited announced the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms effective July 2026. Additionally, Mrs. Aruna Bhinge will complete her tenure as Director on July 6, 2026. These board changes bring extensive scientific and financial expertise to the company's leadership.
Laurus Labs Limited declared an interim dividend of ₹1.2 per equity share for FY 2025-26. The board fixed May 8, 2026, as the record date, with payment scheduled to be completed by May 20, 2026.
Laurus Labs delivered a robust 23% revenue growth in FY26, pivotally shifting its mix toward CDMO which now accounts for 30% of sales while maintaining ARV leadership.
Laurus Labs has appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms effective July 02, 2026. Simultaneously, the company announced the retirement of Independent Director Mrs. Aruna Bhinge effective July 06, 2026, upon completion of her second term.
Laurus Labs Ltd has approved the voluntary closure of its non-material German subsidiary, Laurus Generics GmbH. The subsidiary reported nil turnover for FY 2025-26 and its closure is expected to have no material impact on the company's consolidated financials.
Laurus Labs approved an additional investment of approximately ₹107.80 Crore (EURO 9.8 million) in its joint venture, KRKA Pharma Private Limited. The funds will support KRKA's capital expenditure for setting up a manufacturing facility. The company's shareholding in the JV will remain unchanged at 49%.
Laurus Labs approved the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms starting July 02, 2026. Additionally, Mrs. Aruna Bhinge will retire as an Independent Director on July 06, 2026, upon completing her second term.
Laurus Labs Limited has declared a 2nd Interim Dividend of Rs.1.20 (60%) per equity share for FY 2025-26. The company has fixed May 08, 2026, as the record date. The dividend payment will be made on or after May 20, 2026.
Laurus Labs announced its FY26 results, reporting ₹6,813 Crore in revenue with a 23% year-on-year growth. EBITDA reached ₹1,826 Crore with 26.8% margins, driven by strong CDMO performance and a better product mix. The company declared a second interim dividend of ₹1.2 per share and continues major CAPEX investments for future growth.
Laurus Labs delivered record FY26 results with Revenue up 23% and Net Profit surging 148%, driven by a significant 36% jump in CDMO and improved operating leverage.